Fly News Breaks for June 14, 2018
Jun 14, 2018 | 11:40 EDT
H.C. Wainwright analyst Joseph Pantginis attributes recent weakness in shares of Palatin (PTN) to the relaunch of Addyi by Sprout, and its first-to-market status, following reacquisition of the drug from Valeant (VRX). However, he sees the weakness as undeserved, as he continues to believe that Addyi is an inferior drug with a "sketchy history," Pantginis tells investors. Addyi's "one singular advantage," education and visibility for hypoactive sexual desire disorder, should help the market for Palatin's bremelanotide, which has a "potentially market leading profile," said the analyst, who keeps a Buy rating on Palatin shares.
News For PTN;VRX From the Last 2 Days
Nov 13, 2018 | 07:35 EDT
Reports Q3 EPS (3c).At September 30 the Company had cash, cash equivalents, and accounts receivable aggregating $32.7M, compared to cash and cash equivalents and accounts receivable of $38.0M at June 30. Current liabilities were $8.5M as of September 30, 2018, compared to $10.8M as of June 30.